A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

Clinical trial NCT02214121 · COMPLETED

Trial details

NCT number: NCT02214121
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease

Start date: 2014-09-11
Primary completion: 2017-02-27
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.